SWM
EVGN icon

SHP Wealth Management’s Evogene EVGN Stock Holding History

SHP Wealth Management’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50 Hold
65
– – ﹤0.01% 1791
2025
Q4 		$72 Buy
+65
New +$76 ﹤0.01% 1511

Other funds holding EVGN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $137M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

SHP Wealth Management's EVGN Position: Q1 2026 in Review

SHP Wealth Management held its Evogene (EVGN) position steady in Q1 2026 at 65 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

SHP Wealth Management first reported a position in EVGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $72 in Q4 2025. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

  • SHP Wealth Management held 65 shares of Evogene worth $50 as of Q1 2026.
  • SHP Wealth Management left its Evogene share count unchanged in Q1 2026.
  • Evogene made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1791 holding.
  • SHP Wealth Management first reported a position in Evogene in Q4 2025 and has held it in 2 quarters since.
  • SHP Wealth Management's Evogene position peaked at $72 in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.